Everyday Health on MSN

IVIg to SCIg: Considerations when switching immunoglobulin therapies for primary immunodeficiency

Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, costs, and how each impacts quality of life.
dvm360

New canine cancer detection device relies on AI

A new device for detecting canine cancer can screen for dermal and subcutaneous masses using artificial intelligence (AI).

Spherix Global Insights Highlights Evolving PD-1 Landscape as Subcutaneous Use Grows and Biosimilars Approach across Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Spherix Global Insights reports new findings from its inaugural Market Dynamix(TM): PD-1 Inhibition in Solid Tumors (US) study, based on quantitative and qualitative responses from more than 100 U.S.
Clinical Pain Advisor

Phase 3 Data Support Subcutaneous Anifrolumab for Disease Control in SLE

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
MPR

First Treatment for Menkes Disease: FDA Approves Copper Histidinate

Zycubo is a copper replacement therapy administered via subcutaneous injection to bypass impaired GI absorption in patients with Menkes disease.
Medscape

Subcutaneous Anifrolumab Shows Promise in Lupus Treatment

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...
University of California, San Francisco

Why this Little-Known Birth Control Option Deserves More Attention

Self-administered injectable contraceptives, which are progestin-only shots taken at home every three months, have been ...